Advertisement

Cardiovascular Drugs and Therapy

, Volume 4, Supplement 4, pp 861–865 | Cite as

Cardioprotective effect of trimetazidine in severe ischemic cardiomyopathy

  • H. Bricaud
  • L. Brattier
  • J. L. Barat
  • C. Combe
  • B. Boussens
  • J. Bonnet
Poster Presentations

Summary

The aim of this study was to assess the value of long-term treatment with 60 mg per day of trimetazidine, a cellular antlischemic agent, in comparison with placebo, in patients with ischemic cardiomyopathy controlled by conventional treatments. Twenty patients, with a mean age of 59.5 ±1.6 years, suffering from severe ischemic cardiomyopathy (NYHA IV, 6 patients; NYHA III, 14 patients) confirmed by coronary angiography, were included in the study; four of them suffered from residual angina. All of these patients were receiving long-term treatment with long-acting nitrates associated with digitalis (9 patients), diuretics (15 patients), anticoagulants (13 patients), and antiarrhythmics (11 patients), and were considered to be stabilized at the time of inclusion in the study. The examinations consisted of clinical and laboratory assessment, resting ECG, 24-hour ECG monitoring, X-ray evaluation of cardiac volume (CV), and evaluation of echocardiographic left ventricular shortening (ELVS) and of isotopic ejection fraction (EF). These three parameters were expressed as a percentage variation with respect to the initial value, and their variation between the two groups was compared by means of two-way analysis of variance. Clinically, the therapeutic benefit provided by trimetazidine resulted in: a) an improvement of dyspnea in all patients treated with trimetazicine compared with only one patient with placebo (p < 0.001), b) resolution of residual angina, which was unchanged with placebo, c) reduced requirements for complementary treatments (a single case versus eight cases in the placebo group; p < 0.01). This clinical improvement was corroborated by a significant difference in the variation between the two groups for CV (p=0.03) and EF (p=0.02), and a nonsignificant variation for ELVS (p=0.09). The results demonstrated the beneficial effect of trimetazidine in the long-term treatment of ischemic cardiomyopathy without any associated adverse effects.

Key Words

ischemic cardiomyopathy trimetazidine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bodinier MC, Gargouïl YM, Harpey C. Effet protecteur de la trimétazidine vis-à-vis du taux de calcium ionisé cytosolique. Arch Mal Coeur et Vaisseaux 1988;81391.Google Scholar
  2. 2.
    Fitoussi M, Rochette L, Bralet J et al. Incidences fonctionnelles et métaboliques d'un prétraitement par la trimétazidine au niveau du coeur de rat. Arch Mal Coeur et Vaisseaux 1985;78:460.Google Scholar
  3. 3.
    Renaud JF. Internal pH, Na+ and Ca2+ regulation by trimetazidine during cardiac cell acidosis. Cardiovasc Drugs Ther 1988;1:677–686.Google Scholar
  4. 4.
    Honoré E, Adamantidis MM, Challice CE et al. Cardioprotection by calcium antagonists, piridoxilate and trimetazidine. IRSC Med Sci 1986;14:938–939.Google Scholar
  5. 5.
    Roulet MJ, Garnier D. The anti-anginal drug, trimetazidine, potentiates the tension on hypoxic ductus arteriosus. INSERM 1984;124:481–488.Google Scholar
  6. 6.
    Catroux P, Dorian C, Harpey C, et al. Mise en évidence de l'effet protecteur de la trimétazidine vis-à-via de l'enzymurie induite par clampage du pédicule rénal chez le rat. Néphrologié 1986;7:124.Google Scholar
  7. 7.
    Lavanchy N, Martin J, Rossi A. Anti-ischemic effects of trimetazidine: 31P-NMR spectroscopy in the isolated rat heart. Arch Intern Pharmacodyn Thér 1987;286:97–110.Google Scholar
  8. 8.
    Guarnieri C, Muscari C. Beneficial effects of trimetazidine on mitochondrial function and superoxide production in the cardiac muscle of monocrotaline-treated rats. Biochemic Pharmacol 1988;24:4685–4688.Google Scholar
  9. 9.
    Cruz C, Zaoui A, Ayoub S, et al.. Altérations des myocytes isolés des ventricules de coeur de rat adulte: Protection par la trimétazidine. Concours Médical 1987;36(Suppl):3470–3475.Google Scholar
  10. 10.
    Maridonneau-Parini I, Harpey C. Effect of trimetazidine on membrane damage induced by oxygen free radicals in human red cells. Br J Clin Pharm 1985;20:148–151.Google Scholar
  11. 11.
    Catroux P, Cambar J, Benchekroun N. Antilipoperoxidant effect of trimetazidine in post ischaemic acute renal failure in the rat. In: Emerit I, Packer L, Auclair C, eds. Autioxidants in therapy and preventive medicine. New York: Plenum, 1990, in press.Google Scholar
  12. 12.
    Sellier P, Maurice P. Recherche des effects hémodynamiques de la trimétazidine, en administration unique chez l'homme. Thérapie 1987;42:245–246.Google Scholar
  13. 13.
    Sellier P, Audouin P, Payen B, et al.. Acute effects of trimetazidine evaluated by exercise testing. Eur J Clin Pharmacol 1987;33:205–207.Google Scholar
  14. 14.
    Sellier P. Effets de la trimétazidine sur les paramètres ergométriques dans l'angor d'effort. Etude multicentrique contrôlée à double insu contre placebo. Arch Mal Coeur 1986;9:1331–1336.Google Scholar
  15. 15.
    Didier JP, Moreau D. Pharmacologie d'une nouvelle thérapeutique de l'ischémie: Ses effets sur les performances du coeur isolé et perfusé de rat en normoxie et en hypoxie, Entretiens Bichat, 1980;37–40.Google Scholar

Copyright information

© Kluwer Academic Publishers 1990

Authors and Affiliations

  • H. Bricaud
    • 1
  • L. Brattier
    • 1
  • J. L. Barat
    • 1
  • C. Combe
    • 1
  • B. Boussens
    • 1
  • J. Bonnet
    • 1
  1. 1.Hòpital Cardiologique de Haut LévêquePessacFrance

Personalised recommendations